Filing Details

Accession Number:
0001144204-12-026008
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-05-03 20:51:16
Reporting Period:
2012-05-01
Filing Date:
2012-05-03
Accepted Time:
2012-05-03 20:51:16
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
895051 Entremed Inc ENMD Biological Products, (No Disgnostic Substances) (2836) 581959440
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1542072 W. Tak Mak Entremed, Inc.
9640 Medical Center Drive
Rockville MD 20850
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-05-01 352,857 $0.00 365,376 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Warrants (Right to Buy) Acquisiton 2012-01-20 69,565 $0.00 69,565 $1.40
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
69,565 2012-07-29 2017-07-29 No 5 A Direct
Footnotes
  1. Reflects the conversion price of a certain Subordinated Mandatorily Convertible Note ("Convertible Note") acquired in connection with the Company's strategic financing entered into on January 20, 2012 ("Strategic Financing"). The Convertible Note automatically converts into shares of common stock, at the conversion price of $1.15, upon stockholders approval of the Strategic Financing. The conversion price reflects the 10-day average closing sale price of the Company's Common Stock ending on January 20, 2012. The stockholders approved the Strategic Financing at the Company's Annual Stockholders Meeting held on April 30, 2012 ("2012 Annual Meeting").
  2. Warrants were acquired in connection with the Strategic Financing and become exercisable at any time on or after 90 days following the 2012 Annual Meeting.